“The existing circumstance has uncovered some structural weaknesses while in the EU’s medicines supply chain along with a high dependence on non-EU international locations for active pharmaceutical ingredients,” Kyriakides stated. She encouraged that supply chain difficulties be tackled within an EU pharmaceutical technique predicted to become introduced by the top https://www.rilife.co/infrastructure/